Quantcast
Don't Miss

FDA deals setback to Silver Spring-based United Therapeutics

United Therapeutics Corp., of Silver Spring, received a setback from the Food and Drug Administration when federal regulators, for the second time, rejected the biopharmaceutical company’s new drug application for oral treprostinil, a treatment for pulmonary arterial hypertension, which is high blood pressure in the arteries that supply the lungs.

Print, Digital & Mobile

Monthly Autorenew
$9.99
(special offer!)

----------
3 Months
$84.00

----------
6 Months
$162.00

----------
1 Year
$269.00


Digital & Mobile Only

1 Year
$169.00

 

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

 
Scroll To Top